Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasabuvir
- Development stage
- Phase 4
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dasabuvir is a direct-acting antiviral drug used as part of combination therapy to treat chronic hepatitis C virus (HCV) infection, specifically genotypes 1a and 1b. It is a non-nucleoside NS5B polymerase inhibitor that binds to the palm domain of the HCV NS5B RNA-dependent RNA polymerase, inducing a conformational change that prevents elongation of viral RNA. Dasabuvir must be used in combination with other antivirals such as ombitasvir, paritaprevir, and ritonavir (with or without ribavirin), as monotherapy is not effective. The drug was developed by AbbVie and has been marketed under brand names including Viekira Pak and Viekira XR for the treatment of chronic hepatitis C[2][5][6].
- Brand names
- Viekira PakViekira XR
- Other names
- dasabuvir
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on dasabuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasabuvir.